|Chemical and physical data|
|Molar mass||144,612.59 g·mol−1|
In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lung cancer was granted priority review. A decision by the U.S. Food and Drug Administration is expected by 5 September 2018.
In May 2016 FDA granted accelerated approval to atezolizumab for locally advanced or metastatic urothelial carcinoma treatment after failure of cisplatin-based chemotherapy. The confirmatory trial (to convert the accelerated approval into a full approval) failed to achieve its primary endpoint of overall survival.
In October 2016, FDA approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.
Mechanism of action
Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."
For some cancers (notably bladder) the probability of benefit is related to PD-L1 expression, but most cancers with PD-L1 expression still do not respond, and many (about 15%) without PD-L1 expression do respond.
- "Genentech Presents Positive Results of Atezolizumab in Advanced Bladder Cancer". Oct 2, 2015.
- Shields, Michael (11 Apr 2016). "Roche says FDA fast tracks atezolizumab in specific type of lung cancer". Reuters. Retrieved 11 Apr 2016.
- "FDA approves new, targeted treatment for bladder cancer". FDA. 18 May 2016. Retrieved 20 May 2016.
- "Roche's shocking Tecentriq fail raises red flag for bladder cancer rivals | FiercePharma". www.fiercepharma.com. Retrieved 2017-05-11.
- McKee, Selina (2018-05-08). "First-line use of Roche's Tecentriq given priority review". www.pharmatimes.com. Retrieved 2018-05-08.
- Editorial, Reuters. "Roche's Tecentriq combo wins fast FDA review in race to catch rivals". U.S. Retrieved 2018-05-08.
- Failed confirmatory trial raises questions about atezolizumab for advanced urothelial cancer. June 2017
- "FDA approves new treatment for non-small cell lung cancer". FDA. 18 Oct 2016. Retrieved 18 May 2016.
- FDA Professional Drug Information for Tecentriq.
- Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A. "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1.
- "Search of: MPDL3280A - List Results - ClinicalTrials.gov".
- Bendell, Johanna C.; Kim, Tae Won; Goh, Boon C.; Wallin, Jeffrey; Oh, Do-Youn; Han, Sae-Won; Lee, Carrie B.; Hellmann, Matthew David; Desai, Jayesh; Lewin, Jeremy Howard; Solomon, Benjamin J.; Chow, Laura Quan Man; Miller, Wilson H.; Gainor, Justin F.; Flaherty, Keith; Infante, Jeffrey R.; Das-Thakur, Meghna; Foster, Paul; Cha, Edward; Bang, Yung-Jue. "Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). - 2016 ASCO Annual Meeting Abstracts". Meeting Abstracts.
- "MPDL3280A Shows Activity in Triple-Negative Breast Cancer".